Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 3 1

Status

Recruiting 3

Sponsor Class

OTHER 110NIH 52NETWORK 12INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 2Head & Neck 1Genitourinary 1Breast 1

Conditions

Triple Negative Breast Neoplasms 1Prostatic Neoplasms 1Lung Neoplasms 1Head and Neck Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 604Carboplatin 372Paclitaxel 282Cisplatin 267Gemcitabine 253Pemetrexed 193Bevacizumab 190Docetaxel 188Nivolumab 182Injections 167Cyclophosphamide 147atezolizumab 138Capecitabine 134Fluorouracil 133Oxaliplatin 132Dexamethasone 128Fulvestrant 113durvalumab 112130-nm albumin-bound paclitaxel 110fludarabine 101Cetuximab 100Leucovorin 97Rituximab 94venetoclax 90Lenalidomide 83enzalutamide 77Prednisone 77Azacitidine 74Irinotecan 73Ipilimumab 72

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × X-Rays × 1 year × Clear all
NCT07499674 2026-05-29

VISUALIZE-2

Vergent Bioscience, Inc.

Phase 3 Recruiting
132 enrolled
Thoracic

Lung Neoplasms

NCT07581184 2026-05-12

BActinium-1

Aktis Oncology, Inc.

Phase 1 Recruiting
138 enrolled
Genitourinary

Prostatic Neoplasms

NCT07020117 2026-04-21

A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors

Aktis Oncology, Inc.

Phase 1 Recruiting
150 enrolled
BreastHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡